GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Peijia Medical Ltd (HKSE:09996) » Definitions » Cash Flow from Financing

Peijia Medical (HKSE:09996) Cash Flow from Financing : HK$124.7 Mil (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Peijia Medical Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2023, Peijia Medical received HK$3.0 Mil more from issuing new shares than it paid to buy back shares. It received HK$62.6 Mil from issuing more debt. It paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.0 Mil from paying cash dividends to shareholders. It spent HK$2.9 Mil on other financial activities. In all, Peijia Medical earned HK$62.7 Mil on financial activities for the six months ended in Jun. 2023.


Peijia Medical Cash Flow from Financing Historical Data

The historical data trend for Peijia Medical's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peijia Medical Cash Flow from Financing Chart

Peijia Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial 529.38 2,776.42 908.53 131.15 -

Peijia Medical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -71.22 70.71 63.78 60.96 -

Peijia Medical Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Peijia Medical's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

Peijia Medical's Cash from Financing for the quarter that ended in Jun. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$124.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Peijia Medical  (HKSE:09996) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Peijia Medical's issuance of stock for the six months ended in Jun. 2023 was HK$3.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Peijia Medical's repurchase of stock for the six months ended in Jun. 2023 was HK$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Peijia Medical's net issuance of debt for the six months ended in Jun. 2023 was HK$62.6 Mil. Peijia Medical received HK$62.6 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Peijia Medical's net issuance of preferred for the six months ended in Jun. 2023 was HK$0.0 Mil. Peijia Medical paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Peijia Medical's cash flow for dividends for the six months ended in Jun. 2023 was HK$0.0 Mil. Peijia Medical received HK$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Peijia Medical's other financing for the six months ended in Jun. 2023 was HK$-2.9 Mil. Peijia Medical spent HK$2.9 Mil on other financial activities.


Peijia Medical Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Peijia Medical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Peijia Medical (HKSE:09996) Business Description

Traded in Other Exchanges
N/A
Address
8 Zhongtian Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Peijia Medical Ltd is focused on the interventional procedural, transcatheter valve therapeutic, and the neurointerventional procedural medical device market in China. The company's product candidates include Transcatheter Aortic Valve Replacement products, Transcatheter Mitral Valve Replacement/Transcatheter Tricuspid Valve Replacement products, Ancillary products, Neurointerventional products, and its product pipeline consists of transcatheter valve therapeutic and neurointerventional products and product candidates. Its operating segments are Transcatheter Valve Therapeutic Business and Neurointerventional Business.
Executives
Jinnius Drive Trust 2103 Interests held jointly with another person
Xinyue International Limited 2103 Interests held jointly with another person
Ye Hong 2103 Interests held jointly with another person
Zhang Ping Ye 2103 Interests held jointly with another person
Zhang Yi 2301 Trustee
Hanlindale Trust 2103 Interests held jointly with another person
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Sum-xxiv Holdings Limited 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you

Peijia Medical (HKSE:09996) Headlines

No Headlines